Quintiles IPO Points To Increased Pharma Productivity And Outsourcing
Executive Summary
Slated for May 9, this offering for the largest CRO is expected to attract a wide range of investors, including health care specialists and growth-oriented generalists. The IPO filing shows how the biopharma industry is rebounding. But the CRO’s risk-sharing projects with pharma, which gained attention in recent years, don’t seem to be that productive.
You may also be interested in...
Quintiles Draws Curtain On Phase I India Unit As External Business Environment Gets Challenging
The leading CRO shutters its Phase I unit in Hyderabad inaugurated only two years ago. The decision signifies the tough regulatory challenges global companies are facing in India.
In Advance Of Pharma Partnership, Intarcia Inks Equity Deal With Quintiles
The CRO will conduct Phase III trials on an implantable device that delivers exenatide to Type 2 diabetes patients, while an anticipated pharma partner will help commercialize it around the world.
Social Norms Shift, But U.S. Rules On Cannabis-Related Drug R&D Lag Behind
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?